30 Patients with Acute Myeloid Leukemia (AML), receiving chemotherapy to remission induction randomized, were to receive (Group A) or not (Group B) oral Amphotericin B in tablets, as a prophylaxis against oral and/or gastrointestinal candidiasis. The authors, in fact, used a new preparation (slowly chewing tablets) which allows a more prolonged permanence of the active principle at the level of the throat than the suspension. By the meaning of the results, it was shown that only 2 out 15 patients in the Group A, treated with Amphotericin B, developped oral candidiasis, without intestinal colonization. In the Group B, on the contrary, oral candidiasis was shown in 7 out of 13 patients. The Minimal Inhibitory Concentration of Amphotericin B against the isolated strains was evaluated. At the same time, the specific antibody titres of the patients with proved mycotic infection were evaluated by the authors.
|Translated title of the contribution||Mycotic infections in patients affected by acute myeloid leukemia clinical-microbiological evaluation of a protocol of anti-mycotic prophylaxis|
|Number of pages||4|
|Journal||Giornale di Malattie Infettive e Parassitarie|
|Publication status||Published - 1986|
ASJC Scopus subject areas